Renaissance Capital logo

AIMT News

US IPO Weekly Recap: A bad week besides biotech

Biotech companies lead a weak week in IPOs. So far this year, 127 companies have come public, and the average first-day pop has been about 16%. In the past two weeks, 8 of...read more

Go nuts!: Aimmune Therapeutics prices upsized IPO at $16, the high end of the range

Aimmune Therapeutics, which is developing an oral immunotherapy to desensitize peanut allergies, raised $160 million by offering 10 million shares at $16.00, the high end of the range of $14 to $16. Aimmune Therapeutics plans to list on the Nasdaq under the...read more

Week ahead: 10 IPOs set to price during the week of August 3

August 2015 kicks off with ten IPOs on the calendar for this week - more IPOs than all of August 2014 - after a ...read more

Peanut allergy biotech Aimmune Therapeutics sets terms for $125 million IPO

Aimmune Therapeutics, which is developing an oral immunotherapy designed to lessen the effects of peanut allergies, announced terms for its IPO on Monday. The Brisbane, CA-based company plans to raise $125 million by offering 8.3 million shares at a price...read more